NanoMIPs: Molecularly Imprinted Cavities for Smart and Controlled Anti-Cancer Drug Release.

The inception of molecularly imprinted polymer technology at the nanoscale has marked a major advancement in targeted cancer therapy and diagnostics, representing the first systematic distribution of synthetic substitute to monoclonal antibodies in cancer therapeutics. Nano molecularly imprinted polymers (nanoMIPs) present a significant shift in cancer intervention with an antibody free strategy owing to its high specificity and adaptive recognition potential. Unlike conventional drug delivery platforms, nanoMIPs function as smart nanoscale scaffolds, capable of selectively encapsulating, accumulating and strategically releasing the chemotherapeutic agent in highly aggressive carcinomas and sarcomas. A key advantage of nanoMIPs based drug delivery system is their ability to create molecularly imprinted cavities that retain an exquisite structural memory of the target molecules after their removal establishing the first clinically viable, non biological alternative to therapeutic antibodies. This review provides an in-depth overview of the development, current state, and prospect of nanoMIPs, emphasizing their distinct molecular recognition properties and advantages over conventional antibody-based approach in cancer therapy. Several relevant chemotherapeutic drugs have been discussed for controlled and sustained delivery using nanoMIPs, for an improved biocompatibility, stability, solubility, biodegradability, and targeting efficiency across various cancer types. By integrating recent advancements in nanoMIPs based anticancer drug delivery system, this review seeks to provide a comprehensive framework for their continued development, optimization, and eventual clinical translation as the next generation antibody substitute in precision cancer therapeutics.